[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Lehmann J, Retz M, Steiner G, Albers P, Jaeger E, Knuth A, Lippert C, Koser M, Stockamp K, Otto C, Melchior H, Fassmann C, Potratz C, Loch T, Derigs HG, Becker T, Kälble T, Piechota HJ, Hertle L, Weinknecht S, Weissbach L, Al-Mwalad M, Hamza A, Henss H, Brkovic D, Pomer S, Roloff J, Walz P, Muschter R, Tunn U, Winter E, Bub P, Kaldenbach U, Roth S, Brauers A, Jakse G, Richter AE, Wirth M, Hartlapp J, Van Ahlen H, Stöckle M.
Lehmann J, et al. Among authors: albers p.
Urologe A. 2003 Aug;42(8):1074-86. doi: 10.1007/s00120-003-0317-4. Epub 2003 Apr 2.
Urologe A. 2003.
PMID: 14513232
Clinical Trial.
German.